Freek Verheugt

Showing 1-8 of 8 articles

Author Patrick Serruys

Coronary interventions

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Édes I, van de Harst P, Krackhardt F, Tijssen J, Rademaker-Havinga T, Garg S, Steg P, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

December 20, 2019 | 10.4244/EIJ-D-19-00202

Author Patrick Serruys

Coronary interventions

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial

Serruys P, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Spitzer E, Walsh S, Adlam D, Hildick-Smith D, Edes I, van de Harst P, Krackhardt F, Thijssen J, Rademaker-Havinga T, Garg S, Steg P, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt F

March 17, 2019 | 10.4244/EIJ-D-19-00202

Author Kurt Huber

Coronary interventions

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified

Huber K, Verheugt F

March 20, 2017 | 10.4244/EIJV12I16A315

Author Willem Dewilde

Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial

Dewilde W, Janssen P, Kelder J, Verheugt F, de Smet B, Adrianssens T, Vrolix M, Brueren G, Vandendriessche T, Van Mieghem C, Cornelis K, Vos J, Breet N, ten Berg J

August 20, 2015 | 10.4244/EIJY14M06_07

Author Pascal Vranckx

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients

Vranckx P, Verheugt F, de Maat MP, Ulmans V, Regar E, Smits P, ten Berg J, Lindeboom W, Jones R, Friedman J, Reilly P, Leebeek F

January 18, 2013 | 10.4244/EIJV8I9A162

Author Martial Hamon

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study

Hamon M, Rao S, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E

August 24, 2012 | 10.4244/EIJV8I4A76

Author Bastiaan Zwart

Triggering mechanisms of stent thrombosis

Zwart B, van Werkum J, Heestermans A, Kelder J, Zomer A, van’t Hof A, Verheugt F, ten Berg J

January 20, 2011

Author M Gomes

Effect of PCI on inflammatory markers, adiponectin and insulin resistance

Gomes M, Smits P, Verheugt F, Tack C

February 25, 2010

1

Latest news

EHRA/EAPCI consensus on LAA occlusion, EAPCI Position paper on defining device sucess and more

(3D volume-rendered CCTA LAA example)

January 17, 2020

From Paris to Amsterdam: EuroPCR, ESC 2020 and spotlight on “The Cutting Edge of Cardiology”

January 17, 2020

New this week: Comparing OFR & FFR, Provisional bifurcation stenting procedure and more

January 21, 2020

Access some of the latest Trials: EXCEL 5 years, GALILEO, ISAR-REACT 5 ...

(The Trials book is supported by Biotronik)

January 15, 2020

Guidance Papers

Guidelines, consensus & position papers

The role of the Heart Team in the planning of aortic valve replacement

January 15, 2020

Last week's JAA's: Inferior caval valve implantation for severe tricuspid regurgitation

January 14, 2020

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke